Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 218

1.

Distinct effects of single amino-acid changes to tuberin on the function of the tuberin-hamartin complex.

Nellist M, Sancak O, Goedbloed MA, Rohe C, van Netten D, Mayer K, Tucker-Williams A, van den Ouweland AM, Halley DJ.

Eur J Hum Genet. 2005 Jan;13(1):59-68.

2.

The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.

Nobukini T, Thomas G.

Novartis Found Symp. 2004;262:148-54; discussion 154-9, 265-8. Review.

PMID:
15562827
3.
4.

TSC2 missense mutations inhibit tuberin phosphorylation and prevent formation of the tuberin-hamartin complex.

Nellist M, Verhaaf B, Goedbloed MA, Reuser AJ, van den Ouweland AM, Halley DJ.

Hum Mol Genet. 2001 Dec 1;10(25):2889-98.

PMID:
11741832
5.
6.
7.

Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.

Kwiatkowski DJ.

Cancer Biol Ther. 2003 Sep-Oct;2(5):471-6. Review.

PMID:
14614311
8.

Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin.

Hodges AK, Li S, Maynard J, Parry L, Braverman R, Cheadle JP, DeClue JE, Sampson JR.

Hum Mol Genet. 2001 Dec 1;10(25):2899-905.

PMID:
11741833
9.

Regulation of tuberous sclerosis complex (TSC) function by 14-3-3 proteins.

Nellist M, Goedbloed MA, Halley DJ.

Biochem Soc Trans. 2003 Jun;31(Pt 3):587-91. Review.

PMID:
12773161
10.

Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent.

Karbowniczek M, Cash T, Cheung M, Robertson GP, Astrinidis A, Henske EP.

J Biol Chem. 2004 Jul 16;279(29):29930-7. Epub 2004 May 18.

11.

Tuberin phosphorylation regulates its interaction with hamartin. Two proteins involved in tuberous sclerosis.

Aicher LD, Campbell JS, Yeung RS.

J Biol Chem. 2001 Jun 15;276(24):21017-21. Epub 2001 Apr 4.

12.

Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.

Chan JA, Zhang H, Roberts PS, Jozwiak S, Wieslawa G, Lewin-Kowalik J, Kotulska K, Kwiatkowski DJ.

J Neuropathol Exp Neurol. 2004 Dec;63(12):1236-42.

PMID:
15624760
13.

Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products.

van Slegtenhorst M, Nellist M, Nagelkerken B, Cheadle J, Snell R, van den Ouweland A, Reuser A, Sampson J, Halley D, van der Sluijs P.

Hum Mol Genet. 1998 Jun;7(6):1053-7.

PMID:
9580671
14.

Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.

Jaeschke A, Hartkamp J, Saitoh M, Roworth W, Nobukuni T, Hodges A, Sampson J, Thomas G, Lamb R.

J Cell Biol. 2002 Oct 28;159(2):217-24. Epub 2002 Oct 28.

15.
16.

Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.

Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J.

Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13571-6. Epub 2002 Sep 23.

17.

Tumour suppressors hamartin and tuberin: intracellular signalling.

Krymskaya VP.

Cell Signal. 2003 Aug;15(8):729-39. Review.

PMID:
12781866
18.

Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway.

Jozwiak J, Jozwiak S, Grzela T, Lazarczyk M.

Neuromolecular Med. 2005;7(4):287-96. Review.

PMID:
16391386
20.

Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.

Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J.

Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13489-94. Epub 2004 Sep 1.

Supplemental Content

Support Center